

30 January 2020

ASX Announcement

ADALTA GRANTED US PATENT FOR AD-214

MELBOURNE Australia, 30 January 2019: AdAlta Limited (ASX:1AD), the biotechnology company developing novel therapeutic products from its i-body platform is pleased to announce that a key patent relating to the Company's lead program, AD-214, has been granted by the US Patent and Trademarks Office (USPTO).

US Patent number 10,538,596 is entitled "CXCR4 binding molecules and methods of use thereof" and has an expiration date of 8 January 2036. This patent includes the composition of AD-214 and its use in therapeutic and diagnostic applications, including Idiopathic Pulmonary Fibrosis (IPF), the lead indication for which AD-214 is being developed. The international application for this patent was filed in January 2016 with a priority date of 9 January 2015. Patents are granted on a country by country basis and this is the second patent to be granted under this application. The Australian version was granted in 2017 and the claims are being pursued in other major markets including the European Union and Japan.

AdAlta's CEO, Tim Oldham commented, "This granted patent strengthens AdAlta's patent portfolio and in particular provides protection for AD-214 in the largest pharmaceutical and IPF market in the world. Strong intellectual property protection is essential to our partnering and commercialization strategy."

Authorised for lodgment by:

Tim Oldham

CEO and Managing Director

-ENDS-

Notes to Editors About AdAlta

AdAlta Limited is an Australian-based drug development company headquartered in Melbourne. The Company is using its proprietary technology platform to generate a promising new class of single domain antibody protein therapeutics, known as i-bodies, that have the potential to treat some of today's most challenging medical conditions. The technology mimics the shape and stability of a crucial antigen-binding domain, that was discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, capable of uniquely interacting with previously difficult to access targets such as G-protein coupled receptors and ion channels that are implicated in many serious diseases.

AdAlta is currently preparing for its Phase 1 clinical studies for its lead i-body candidate, AD-214. The clinical program is expected to commence in mid-2020 following clinical trial design finalisation and completion of a pre-clinical study to inform dose levels. AD-214 is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need. The Company is also in collaborative partnerships to advance the development of its i-body platform. It has an agreement with UK-based research organisation, Excellerate Bioscience to collaborate on an undisclosed target of commercial interest and an agreement with GE Healthcare for diagnostic imaging agents against several drug targets, including Granzyme B.

AdAlta plans to continue further drug discovery and development directed towards other drug targets and diseases.

Further information can be found at: www.adalta.com.au

For more information, please contact:

Investors

Tim Oldham, CEO & Managing Director

Tel: +61 403 446 665

E: t.oldham@adalta.com.au

Media

IR Department

Tel: +61 411 364 382

E: gabriella.hold@irdepartment.com.au